High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves

Murat Gencbay, Fikret Turan, Muzaffer Degertekin, Nilüfer Eksi, Bulent Mutlu, Aynur Unalp

Research output: Contribution to journalArticle

Abstract

Background and aims of the study: Thrombosis is one of the most feared and life-threatening complications of mechanical heart valves (MHV), with an incidence of 1-3 per 100 patient-years. Hypercoagulable states are highly prevalent in the general population and can predispose MHV to thrombus formation. Thus, we conducted a study to investigate the frequency of hypercoagulable states in patients with MHV who had recurrent thrombosis at least twice after valve implantation. Methods: Fifteen patients (mean age 42 ± 11 years; range: 18 to 55 years) with recurrent thrombosis of MHV (2.4 ± 0.8 recurrences/patient) (group 1) and 15 matched patients (mean age 40 ± 12 years; range: 18 to 55 years) with MHV without thrombosis (group 2) were followed up with transthoracic and transesophageal echocardiography. Patients' sera were monitored for antibodies to cardiolipin (ACLA-IgG and ACLA-IgM), phosphatidylserine (APSA), lupus-type anticoagulant (LA) and lipoprotein(a) (LP(a)). Results: Average values for group 1 versus group 2 were: ACLA-IgG (normal range 0.05). The frequency of abnormally high levels of ACLA-IgG was 9/15 in group 1 and 0/15 in group 2 (p0.05); of APSA, 1/15 in group 1 and 0/15 in group 2 (p>0.05); and of LP(a), 5/15 in group 1 and 0/15 in group 2 (p

Original languageEnglish (US)
Pages (from-to)601-609
Number of pages9
JournalJournal of Heart Valve Disease
Volume7
Issue number6
StatePublished - Nov 1998

Fingerprint

Heart Valves
Thrombosis
Immunoglobulin G
Lipoprotein(a)
Phosphatidylserines
Immunoglobulin M
Lupus Coagulation Inhibitor
Cardiolipins
Transesophageal Echocardiography
Echocardiography
Reference Values
Recurrence
Antibodies
Incidence
Serum
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gencbay, M., Turan, F., Degertekin, M., Eksi, N., Mutlu, B., & Unalp, A. (1998). High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves. Journal of Heart Valve Disease, 7(6), 601-609.

High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves. / Gencbay, Murat; Turan, Fikret; Degertekin, Muzaffer; Eksi, Nilüfer; Mutlu, Bulent; Unalp, Aynur.

In: Journal of Heart Valve Disease, Vol. 7, No. 6, 11.1998, p. 601-609.

Research output: Contribution to journalArticle

Gencbay, M, Turan, F, Degertekin, M, Eksi, N, Mutlu, B & Unalp, A 1998, 'High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves', Journal of Heart Valve Disease, vol. 7, no. 6, pp. 601-609.
Gencbay, Murat ; Turan, Fikret ; Degertekin, Muzaffer ; Eksi, Nilüfer ; Mutlu, Bulent ; Unalp, Aynur. / High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves. In: Journal of Heart Valve Disease. 1998 ; Vol. 7, No. 6. pp. 601-609.
@article{1f02ef826f72441c9e1ec935794d6ba6,
title = "High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves",
abstract = "Background and aims of the study: Thrombosis is one of the most feared and life-threatening complications of mechanical heart valves (MHV), with an incidence of 1-3 per 100 patient-years. Hypercoagulable states are highly prevalent in the general population and can predispose MHV to thrombus formation. Thus, we conducted a study to investigate the frequency of hypercoagulable states in patients with MHV who had recurrent thrombosis at least twice after valve implantation. Methods: Fifteen patients (mean age 42 ± 11 years; range: 18 to 55 years) with recurrent thrombosis of MHV (2.4 ± 0.8 recurrences/patient) (group 1) and 15 matched patients (mean age 40 ± 12 years; range: 18 to 55 years) with MHV without thrombosis (group 2) were followed up with transthoracic and transesophageal echocardiography. Patients' sera were monitored for antibodies to cardiolipin (ACLA-IgG and ACLA-IgM), phosphatidylserine (APSA), lupus-type anticoagulant (LA) and lipoprotein(a) (LP(a)). Results: Average values for group 1 versus group 2 were: ACLA-IgG (normal range 0.05). The frequency of abnormally high levels of ACLA-IgG was 9/15 in group 1 and 0/15 in group 2 (p0.05); of APSA, 1/15 in group 1 and 0/15 in group 2 (p>0.05); and of LP(a), 5/15 in group 1 and 0/15 in group 2 (p",
author = "Murat Gencbay and Fikret Turan and Muzaffer Degertekin and Nil{\"u}fer Eksi and Bulent Mutlu and Aynur Unalp",
year = "1998",
month = "11",
language = "English (US)",
volume = "7",
pages = "601--609",
journal = "Journal of Heart Valve Disease",
issn = "0966-8519",
publisher = "ICR Publishers Ltd",
number = "6",

}

TY - JOUR

T1 - High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves

AU - Gencbay, Murat

AU - Turan, Fikret

AU - Degertekin, Muzaffer

AU - Eksi, Nilüfer

AU - Mutlu, Bulent

AU - Unalp, Aynur

PY - 1998/11

Y1 - 1998/11

N2 - Background and aims of the study: Thrombosis is one of the most feared and life-threatening complications of mechanical heart valves (MHV), with an incidence of 1-3 per 100 patient-years. Hypercoagulable states are highly prevalent in the general population and can predispose MHV to thrombus formation. Thus, we conducted a study to investigate the frequency of hypercoagulable states in patients with MHV who had recurrent thrombosis at least twice after valve implantation. Methods: Fifteen patients (mean age 42 ± 11 years; range: 18 to 55 years) with recurrent thrombosis of MHV (2.4 ± 0.8 recurrences/patient) (group 1) and 15 matched patients (mean age 40 ± 12 years; range: 18 to 55 years) with MHV without thrombosis (group 2) were followed up with transthoracic and transesophageal echocardiography. Patients' sera were monitored for antibodies to cardiolipin (ACLA-IgG and ACLA-IgM), phosphatidylserine (APSA), lupus-type anticoagulant (LA) and lipoprotein(a) (LP(a)). Results: Average values for group 1 versus group 2 were: ACLA-IgG (normal range 0.05). The frequency of abnormally high levels of ACLA-IgG was 9/15 in group 1 and 0/15 in group 2 (p0.05); of APSA, 1/15 in group 1 and 0/15 in group 2 (p>0.05); and of LP(a), 5/15 in group 1 and 0/15 in group 2 (p

AB - Background and aims of the study: Thrombosis is one of the most feared and life-threatening complications of mechanical heart valves (MHV), with an incidence of 1-3 per 100 patient-years. Hypercoagulable states are highly prevalent in the general population and can predispose MHV to thrombus formation. Thus, we conducted a study to investigate the frequency of hypercoagulable states in patients with MHV who had recurrent thrombosis at least twice after valve implantation. Methods: Fifteen patients (mean age 42 ± 11 years; range: 18 to 55 years) with recurrent thrombosis of MHV (2.4 ± 0.8 recurrences/patient) (group 1) and 15 matched patients (mean age 40 ± 12 years; range: 18 to 55 years) with MHV without thrombosis (group 2) were followed up with transthoracic and transesophageal echocardiography. Patients' sera were monitored for antibodies to cardiolipin (ACLA-IgG and ACLA-IgM), phosphatidylserine (APSA), lupus-type anticoagulant (LA) and lipoprotein(a) (LP(a)). Results: Average values for group 1 versus group 2 were: ACLA-IgG (normal range 0.05). The frequency of abnormally high levels of ACLA-IgG was 9/15 in group 1 and 0/15 in group 2 (p0.05); of APSA, 1/15 in group 1 and 0/15 in group 2 (p>0.05); and of LP(a), 5/15 in group 1 and 0/15 in group 2 (p

UR - http://www.scopus.com/inward/record.url?scp=0031765448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031765448&partnerID=8YFLogxK

M3 - Article

C2 - 9870192

AN - SCOPUS:0031765448

VL - 7

SP - 601

EP - 609

JO - Journal of Heart Valve Disease

JF - Journal of Heart Valve Disease

SN - 0966-8519

IS - 6

ER -